- Home
- PSHG vs ALGS Comparison
PSHG vs ALGS Comparison
Compare PSHG & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSHG
- ALGS
- Stock Information
- Founded
- PSHG 2010
- ALGS 2018
- Country
- PSHG Greece
- ALGS United States
- Employees
- PSHG N/A
- ALGS N/A
- Industry
- PSHG Marine Transportation
- ALGS Biotechnology: Pharmaceutical Preparations
- Sector
- PSHG Consumer Discretionary
- ALGS Health Care
- Exchange
- PSHG Nasdaq
- ALGS Nasdaq
- Market Cap
- PSHG 23.7M
- ALGS 27.7M
- IPO Year
- PSHG N/A
- ALGS 2020
- Fundamental
- Price
- PSHG $1.86
- ALGS $7.21
- Analyst Decision
- PSHG Strong Buy
- ALGS Strong Buy
- Analyst Count
- PSHG 1
- ALGS 1
- Target Price
- PSHG $6.50
- ALGS $75.00
- AVG Volume (30 Days)
- PSHG 36.9K
- ALGS 62.3K
- Earning Date
- PSHG 11-25-2024
- ALGS 10-31-2024
- Dividend Yield
- PSHG N/A
- ALGS N/A
- EPS Growth
- PSHG N/A
- ALGS N/A
- EPS
- PSHG 1.47
- ALGS N/A
- Revenue
- PSHG $90,833,000.00
- ALGS $7,967,000.00
- Revenue This Year
- PSHG N/A
- ALGS N/A
- Revenue Next Year
- PSHG $4.84
- ALGS N/A
- P/E Ratio
- PSHG $1.26
- ALGS N/A
- Revenue Growth
- PSHG N/A
- ALGS N/A
- 52 Week Low
- PSHG $1.60
- ALGS $6.76
- 52 Week High
- PSHG $2.58
- ALGS $30.00
- Technical
- Relative Strength Index (RSI)
- PSHG 49.53
- ALGS 36.55
- Support Level
- PSHG $1.84
- ALGS $6.84
- Resistance Level
- PSHG $1.93
- ALGS $7.85
- Average True Range (ATR)
- PSHG 0.06
- ALGS 0.71
- MACD
- PSHG 0.00
- ALGS 0.08
- Stochastic Oscillator
- PSHG 61.54
- ALGS 14.95
About PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates eight Aframax tanker vessels.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.